Cookies?
Library Header Image
LSE Research Online LSE Library Services

European Medicines Agency’s Priority Medicines (PRIME) scheme at 2 years: an evaluation of clinical studies supporting eligible drugs

Neez, Emilie Marie Celine Anne, Hwang, Thomas, Sahoo, Samali Anova and Naci, Huseyin (2019) European Medicines Agency’s Priority Medicines (PRIME) scheme at 2 years: an evaluation of clinical studies supporting eligible drugs. Clinical Pharmacology and Therapeutics. ISSN 0009-9236 (In Press)

[img] Text (12771_1_merged_1569351353) - Accepted Version
Pending embargo until 1 January 2100.

Download (798kB) | Request a copy

Abstract

The Priority Medicines (PRIME) scheme was launched by the European Medicines Agency (EMA) in 2016 to expedite the development and approval of promising products targeting conditions with high unmet medical need. Manufacturers of PRIME drugs receive extensive regulatory advice on their trial designs. Until June 2018, EMA granted PRIME status to 39 agents, evaluated in 138 studies (102 initiated before and 36 after PRIME eligibility). A third of studies forming the basis of PRIME designation were RCTs and a quarter were blinded. There was no statistically significant difference between trials initiated before and after PRIME designation in terms of randomised design and use of blinding. However, significantly more efficacy studies included a clinical endpoint after PRIME designation than before, and significantly fewer included surrogate measures alone. There were no statistically significant differences between the trial designs of PRIME and non-PRIME-designated products.

Item Type: Article
Official URL: https://ascpt.onlinelibrary.wiley.com/journal/1532...
Additional Information: © The Authors
Divisions: Health Policy
LSE Health
Date Deposited: 18 Oct 2019 11:12
Last Modified: 15 Nov 2019 00:18
URI: http://eprints.lse.ac.uk/id/eprint/102150

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year

View more statistics